

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The Evaluation of effectiveness of betadine (Povidone-iodine) in one step and two step procedure in the treatment of patients with pleural effusion resistant to conventional treatments: a clinical trial

Protocol summary

Study aim

The aim of this study was to evaluate the effectiveness of betadine as a chemical agent for pleurisy, which will be performed in two steps.

Design

This study was performed on 40 patients with refractory pleural effusion. The present intervention involves injecting 20 cc of 10% betadine with 5 cc of lidocaine and 60 cc of normal saline. The injection is done through a catheter. Two hours after the injection, the catheter is closed and the position is changed, and after 2 hours, the catheter valve is opened again, and finally, after 24 hours, the catheter is removed. After the intervention, patients are cared for.

Settings and conduct

The present study is a clinical trial with one arm that will be performed in 1400 in Afzalipour Hospital in Kerman. In this study, which will be done as a pilot

Participants/Inclusion and exclusion criteria

In this study, patients with refractory pleural effusion with adhesions and a history of VATS and thoracoscopy met the inclusion criteria.

Intervention groups

In this study, patients with refractory pleural effusion with adhesions and a history of VATS and thoracoscopy met the inclusion criteria. The present intervention included injection of 20 cc of 10% betadine with 5 cc of lidocaine and 60 cc of normal saline. The injection is done through a catheter. Two hours after the injection, the catheter is closed and the position is changed, and after 2 hours, the catheter valve is opened again, and finally, after 24 hours, the catheter is removed. After the intervention, patients are cared for.

Main outcome variables

Age, sex, type of pleural effusion, duration of follow-up, effectiveness, side effects, reduction of pleural effusion, reduction of clinical symptoms

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220117053750N1**

Registration date: **2022-02-28, 1400/12/09**

Registration timing: **registered_while_recruiting**

Last update: **2022-02-28, 1400/12/09**

Update count: **0**

Registration date

2022-02-28, 1400/12/09

Registrant information

Name

Frank Salajegheh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 34 3132 8325

Email address

f.salajegheh@kmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-03-21, 1400/01/01

Expected recruitment end date

2022-03-20, 1400/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The Evaluation of effectiveness of betadine (Povidone-iodine) in one step and two step procedure in the treatment of patients with pleural effusion resistant to conventional treatments: a clinical trial

Public title

The Evaluation of effectiveness of betadine (Povidone-iodine) in one step and two step procedure in the treatment of patients with pleural effusion resistant to conventional treatments: a clinical trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

In this study, patients with refractory pleural effusion with adhesions and a history of VATS and thoracoscopy are eligible for the study.

Exclusion criteria:

In contrast, patients who have a mass for whom catheterization is not possible will be excluded from the study process

Age

No age limit

Gender

Both

Phase

1-2

Groups that have been masked

No information

Sample size

Target sample size: 40

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Kerman University of Medical Sciences

Street address

Emam Blv., Afzalipour Hospital

City

Kerman

Province

Kerman

Postal code

7616913355

Approval date

2022-01-22, 1400/11/02

Ethics committee reference number

IR.KMU.AH.REC.1400.158

Health conditions studied

1

Description of health condition studied

Resistant pleural effusion

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Pleural effusion, reduction of pleural effusion

Timepoint

monthly

Method of measurement

Ultrasound of the pleural space

Secondary outcomes

1

Description

Reduce dyspnea and cough

Timepoint

One week after pleural effusion injection

Method of measurement

In this study, a data collection form (Checklist) will be used to collect data. This form consists of 4 main parts. In the first part, the demographic characteristics of patients, including age and sex, as well as the type of pleural effusion disease, which is benign and malignant, are recorded. In the second part, the form of thyroid and kidney enzymes are recorded before and after the intervention. In the third part of the form, the length of the follow-up period and the final outcome of the treatment, which includes the success of the treatment and the failure of the treatment, are recorded. Side effects and patient complaints including chest pain, fever, shortness of breath, hypotension, vision loss, and air leakage are recorded at the end of the form.

Intervention groups

1

Description

Intervention group: In this study, 20 patients received betadine in one step. 20 cc of 10% betadine is injected with 60 cc of normal saline and 5 cc of lidocaine and the catheter is removed and two weeks after betadine injection is removed with a needle. In the second group, we inject 10 cc of betadine along with 30 cc of normal

saline and 5 cc of lidocaine and hold the catheter. Two weeks later, we inject 10 cc of betadine with 30 cc of normal saline and 5 cc of lidocaine. Two hours after the injection, the catheter is closed and the position is changed, and after 2 hours, the catheter valve is opened again, and finally, after 24 hours, the catheter is removed, and the patients return two weeks later to remove the betadine. After the intervention, patients are cared for.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Afzalipour Hospital

Full name of responsible person

Faranak Salajegheh

Street address

Emam Blv., Afzalipour Hospital

City

kerman

Province

Kerman

Postal code

7616913355

Phone

+98 34 3132 8325

Email

f.salajegheh@kmu.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Faranak Salajegheh

Street address

Emam Blv., Afzalipour Hospital

City

Kerman

Province

Kerman

Postal code

7616913355

Phone

+98 34 3132 8325

Email

f.salajegheh@kmu.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Kerman University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Faranak Salajegheh

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Internal Medicine

Street address

Emam Blv., Afzalipou Hospital

City

Kerman

Province

Kerman

Postal code

7616913355

Phone

+98 34 3132 8325

Email

f.salajegheh@kmu.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Faranak Salajegheh

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Internal Medicine

Street address

Emam Blv., Afzalipour Hospital

City

Kerman

Province

Kerman

Postal code

7616913355

Phone

+98 34 3132 8325

Email

f.salajegheh@kmu.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Faranak Salajegheh

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Internal Medicine

Street address

Emam Blv., Afzalipour Hospital

City

Kerman

Province

Kerman

Postal code

7616913355

Phone

+98 34 3132 8325

Email

f.salajegheh@kmu.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

The clinical results obtained from the study are published in the article while maintaining the confidentiality of patient data.

When the data will become available and for how long

The information obtained from the test results will be published in the article no later than 12 months later.

To whom data/document is available

Academic and scientific researchers

Under which criteria data/document could be used

Academic and scientific researchers with the condition of maintaining the confidentiality of patients' information

From where data/document is obtainable

Email the responsible author

What processes are involved for a request to access data/document

After requesting in the email and confirmation of the researcher, the requested information will be sent via Orchid two weeks later.

Comments